Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 18, Issue 11, 2012, Pages 2169-2179

  Serada, Satoshi ^a   Fujimoto, Minoru ^a   Terabe, Fumitaka ^a,b   Iijima, Hideki ^b   Shinzaki, Shinichiro ^b   Matsuzaki, Shinya ^b   Ohkawara, Tomoharu ^a   Nezu, Riichiro ^c   Nakajima, Sachiko ^b   Kobayashi, Taku ^d   Plevy, Scott Eric ^d   Takehara, Tetsuo ^b   Naka, Tetsuji ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; DSS; IBD; leucine rich alpha 2 glycoprotein; ulcerative colitis

Indexed keywords

ALPHA2 GLYCOPROTEIN; BIOLOGICAL MARKER; DEXTRAN SULFATE; INTERLEUKIN 22; INTERLEUKIN 6; LEUCINE RICH ALPHA2 GLYCOPROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; WESTERN BLOTTING;

ADULT; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CYTOKINES; DISEASE PROGRESSION; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84867573123     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22936     Document Type: Article

References (28)

1. Nikolaus S, Schreiber S,. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007; 133: 1670-1689.
2. Baumgart DC, Sandborn WJ,. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 1641-1657.
3. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (Suppl 1): i1-15.
4. Caprilli R, Viscido A, Latella G,. Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 92-101.
5. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-1385.
6. Sands BE, Abreu MT, Ferry GD, et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005; 11 (Suppl 1): S22-28.
7. Freeman HJ,. Use of the Crohn's disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008; 14: 4127-4130.
8. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
9. Vermeire S, Van Assche G, Rutgeerts P,. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 661-665.
10. Pepys MB, Druguet M, Klass HJ, et al. Immunological studies in inflammatory bowel disease. Ciba Found Symp 1977: 283-304.
11. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut. 1986; 27: 809-813.
12. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141: 1194-1201.
13. Serada S, Fujimoto M, Ogata A, et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 2010; 69: 770-774.
14. Haupt H, Baudner S,. Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum [author's transl]. Hoppe Seylers Z Physiol Chem. 1977; 358: 639-646.
15. Takahashi N, Takahashi Y, Putnam FW,. Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc Natl Acad Sci U S A. 1985; 82: 1906-1910.
16. Shirai R, Hirano F, Ohkura N, et al. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun. 2009; 382: 776-769.
17. O'Donnell LC, Druhan LJ, Avalos BR,. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol. 2002; 72: 478-485.
18. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298: 82-86.
19. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001; 49: 783-789.
20. Matts SG,. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961; 30: 393-407.
21. Iwahori K, Serada S, Fujimoto M, et al. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Int J Cancer. 2011; 129: 1005-1017.
22. Kim A, Enomoto T, Serada S, et al. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 2009; 125: 2316-2322.
23. Fujimoto M, Nakano M, Terabe F, et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol. 2011; 186: 32-40.
24. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991; 32: 913-917.
25. Woywodt A, Ludwig D, Neustock P, et al. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999; 11: 267-276.
26. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005; 129: 969-984.
27. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990; 98: 694-702.
28. Kentsis A, Lin YY, Kurek K, et al. Discovery and validation of urine markers of acute pediatric appendicitis using high-accuracy mass spectrometry. Ann Emerg Med. 2010; 55: 62-70 e4.